Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Blood (2025) 146 (Supplement 1): 5102.

https://doi.org/10.1182/blood-2025-5102

Published: 2025

Journal Articles

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Elisabetta Todisco, Ivana Lotesoriere, Federico Lussana, Valentina Mancini, Federica Gigli, Cristina Papayannidis, Michela Rondoni, Felicetto Ferrara, Sara Mastaglio, Annalina Piccioni, Michelina Dargenio, Andrea Corbingi, Francesco Mannelli, Alessandro Cignetti, Patrizia Zappasodi, Maria Paola Martelli, Monia Lunghi, Luana Fianchi, Patrizia Chiusolo, Francesco Grimaldi, Federica Pilo, Carla Fili, Debora Capelli, Massimo Breccia, Monica Bocchia, Monica Fumagalli, Sara Galimberti, Luca Maurillo, Calogero Vetro, Alessandra Sperotto, Caterina Patti, Erika Borlenghi, Federica Lessi, Alessandro Isidori, Raffaele Palmieri, Caterina Alati, Samuele Gatani, Chiara Pessina, Paola Minetto, Carola Riva, Marco Frigeni, Nicola Stefano Fracchiolla, Carla Mazzone, Marco Cerrano, Massimo Bernardi, Michele Gottardi, Roberto Cairoli, Adriano Venditti, Livio Pagano, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2025-4608

Published: 2025

Journal Articles

Incidence of infectious complications in Acute Myeloid Leukemia patients undergoing induction chemotherapy with or without fluoroquinolone prophylaxis in real-life: Results from INFLUENCER study

Blood (2025) 146 (Supplement 1): 993.

https://doi.org/10.1182/blood-2025-993

Published: 2025

Journal Articles

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Blood (2025) 146 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2025-3438

Published: 2025

Journal Articles

Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study

Blood (2025) 146 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2025-3384

Published: 2025

Journal Articles

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

Blood (2025) 146 (Supplement 1): 6967.

https://doi.org/10.1182/blood-2025-6967

Published: 2025

Journal Articles

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Mariangela Di Trani, Cristina Skert, Loredana Elia, Giada Almici, Irene Della Starza, Deborah Cardinali, Vittorio Bellomarino, Stefano Soddu, Monica Messina, Martina Rachele Marino, Maria Stefania De Propris, Erika Borlenghi, Francesco Di Raimondo, Michela Ansuinelli, Caterina Alati, Daniele G. Mattei, Valentina Mancini, Patrizia Chiusolo, Barbara Scappini, Maria Paola Martelli, Prassede Salutari, Marco Cerrano, Bianca Serio, Antonella Cucca, Mario Luppi, Daniele Vallisa, Crescenza Pasciolla, Claudio Romani, Martina Chiarucci, Federico Mosna, Massimiliano Bonifacio, Nicola Stefano Fracchiolla, Monica Bocchia, Silvia Imbergamo, Catello Califano, Giuseppe Rodolfo Nunziata, Mario Annunziata, Antonino Mule', Patrizia Zappasodi, Fabio Giglio, Daniela Pietrasanta, Matteo Della Porta, Maurizio Musso, Monia Lunghi, Francesco Zaja, Elisabetta Todisco, Claudia Maria Basilico, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà

Blood (2025) 146 (Supplement 1): 439.

https://doi.org/10.1182/blood-2025-439

Published: 2025

Journal Articles

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study

Blood (2025) 146 (Supplement 1): 5127.

https://doi.org/10.1182/blood-2025-5127

Published: 2025

Journal Articles

Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level

Alfredo Marchetti, Francesca Lazzaroni, Matteo Claudio Da Vià, Alessio Marella, Antonio Matera, Akihiro Maeda, Nicolo Rampi, Claudia Leoni, Federico Mazzon, Elena Tagliaferri, Mariarita Sciumè, Marta Lionetti, Bruno Fattizzo, Francesco Passamonti, Nicola Stefano Fracchiolla, Niccolò Bolli

Blood (2024) 144 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2024-208253

Published: 2024

Journal Articles

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

Blood (2024) 144 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2024-210042

Published: 2024

Journal Articles

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Blood (2019) 134 (12): 935–945.

https://doi.org/10.1182/blood.2018886960

Published: 2019

Includes: Supplemental data

Journal Articles

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Patrizia Zappasodi, MD, Laura Marbello, MD, Erika Borlenghi, MD, Monica Fumagalli, MD, Massimo Bernardi, MD, Nicola Stefano Fracchiolla, MD, Matteo Da Vià, MD, Marianna Rossi, MD, Emanuele Ravano, MD, Elisa Cerqui, MD, Virginia Valeria Ferretti, PhD, Mario Cazzola, Prof, Carlo Castagnola, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 3740.

https://doi.org/10.1182/blood.V126.23.3740.3740

Published: 2015

Journal Articles

Peripherally Inserted Central Catheters (PICCs) Implantation in the Clinical Management of Oncohematologic Patients: Results of a Large Multicenter, Retrospective Study of the REL Group (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy)

Nicola Stefano Fracchiolla, MD, Elisabetta Todisco, MD PhD, Andrea Bilancia, Sara Gandolfi, MD, Valentina Mancini, MD, Laura Marbello, MD, Massimo Bernardi, MD, Andrea Assanelli, MD, Nicola Orofino, MD, Ramona Cassin, MD, Mariarita Sciumè, MD, Francesca Guidotti, MD, Roberto Cairoli, MD, Fabio Ciceri, MD, Armando Santoro, MD, Agostino Cortelezzi, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 5611.

https://doi.org/10.1182/blood.V126.23.5611.5611

Published: 2015

Journal Articles

Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis

Claudia Vener, Nicola Stefano Fracchiolla, Umberto Gianelli, Rossella Calori, Franca Radaelli, Alessandra Iurlo, Sabrina Caberlon, Giancarla Gerli, Leonardo Boiocchi, Giorgio Lambertenghi Deliliers

Blood (2008) 111 (4): 1862–1865.

https://doi.org/10.1182/blood-2007-09-112953

Published: 2008

Journal Articles

Pathogenetic Role of Mature and Progenitor Endothelial Cells in Pre-Eclampsia.

Agostino Cortelezzi, MD, Nicola Stefano Fracchiolla, MD, Michela Cortiana, Biol.Sci, Maria Cristina Pasquini, MD, Ilaria Silvestris, ABT, Irene Cetin, MD, Veronica Cozzi, MD, Giorgio Pardi, MD, Giorgio Lambertenghi Deliliers, MD

Blood (2006) 108 (11): 3946.

https://doi.org/10.1182/blood.V108.11.3946.3946

Published: 2006

Journal Articles

EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid Leukemias

Nicola Stefano Fracchiolla, Gualtiero Colombo, Palma Finelli, Anna Teresa Maiolo, Antonino Neri

Blood (1998) 92 (9): 3481–3484.

https://doi.org/10.1182/blood.V92.9.3481

Published: 1998

Journal Articles

FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma

Nicola Stefano Fracchiolla, Stefano Luminari, Luca Baldini, Luigia Lombardi, Anna Teresa Maiolo, Antonino Neri

Blood (1998) 92 (8): 2987–2989.

https://doi.org/10.1182/blood.V92.8.2987

Published: 1998

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Incidence of infectious complications in Acute Myeloid Leukemia patients undergoing induction chemotherapy with or without fluoroquinolone prophylaxis in real-life: Results from INFLUENCER study

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study

Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Peripherally Inserted Central Catheters (PICCs) Implantation in the Clinical Management of Oncohematologic Patients: Results of a Large Multicenter, Retrospective Study of the REL Group (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy)

Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis

Pathogenetic Role of Mature and Progenitor Endothelial Cells in Pre-Eclampsia.

EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid Leukemias

FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only